Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Soham ShuklaDhvani ShahAlan A MartinNancy A RisebroughRobyn KendallClaus F VogelmeierIsabelle H BoucotLee TombsBjermer LeifPaul W JonesEdward M KerwinChris ComptonFrancois MaltaisDavid A LipsonAfisi S IsmailaPublished in: International journal of chronic obstructive pulmonary disease (2021)
Based on model predictions from a UK perspective, symptomatic patients with COPD and no exacerbations in the prior year receiving umeclidinium/vilanterol are expected to have better outcomes at lower costs versus umeclidinium and salmeterol.